Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | GALK1 | P51570 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.37 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24916266 | 0.84 | KDM4E (0.42) | KDM4ETDP1TNFPDE4APDE4B | |
| SCHEMBL14471172 | 0.82 | KDM4E (0.41) | KDM4ETDP1TNFPDE4APDE4B | |
| SCHEMBL31104421 | 0.81 | KDM4E (0.41) | KDM4ETDP1TNFPDE4APDE4B | |
| SCHEMBL15466928 | 0.81 | KDM4E (0.41) | KDM4ETDP1TNFPDE4APDE4B | |
| SCHEMBL21931156 | 0.77 | MAPK1 (0.37) | KDM4ETDP1HSD17B10PKMKMT2A | |
| SCHEMBL21931145 | 0.77 | CYP1A2 (0.39) | KDM4EPOLBELANEKMT2AALDH1A1 | |
| SCHEMBL4069129 | 0.77 | MEN1 (0.43) | KDM4EHSD17B10GAAKMT2AALDH1A1 | |
| SCHEMBL16166889 | 0.75 | BRPF1 (0.37) | KDM4EPDE4DPOLBHSD17B10ALDH1A1 | |
| SCHEMBL123411 | 0.74 | GAA (0.47) | KDM4ETDP1TNFPDE4APDE4B | |
| SCHEMBL29705981 | 0.74 | GAA (0.47) | KDM4ETDP1TNFPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-07-04 | — | — | US | disclosed |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-07-04 | — | — | US | disclosed |
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11834689-B2 | Incorporation of unnatural nucleotides and methods thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834689-B2 | Incorporation of unnatural nucleotides and methods thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-7595306-B2 | Method of treating neurodegenerative disease | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-29 | — | — | US | disclosed |
| US-7595306-B2 | Method of treating neurodegenerative disease | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-29 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| US-20070275914-A1 | Therapeutic Compositions | BANK OF AMERICA, N.A. | 2007-11-29 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | KDM4E 4076/4885TDP1 95/4885TNF 1413/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | KDM4E 1986/4885TDP1 3469/4885TNF 4283/4885 |
| US-20070161595-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | KDM4E 3524/4885TDP1 447/4885TNF 3482/4885 |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | SLC35B2, SLC29A2, PNP | KDM4E 4151/4885TDP1 835/4885TNF 3926/4885 |
| US-20070275914-A1 | Therapeutic Compositions | AGO2, EXOSC5, RNASE1 | KDM4E 1080/4885TDP1 1826/4885TNF 2201/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | KDM4E 4759/4885TDP1 3768/4885TNF 1413/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | KDM4E 3196/4885TDP1 263/4885TNF 2003/4885 |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | SLC35B2, SLC29A2, PNP | KDM4E 4151/4885TDP1 835/4885TNF 3926/4885 |
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CAT, MPO, NISCH | KDM4E 4759/4885TDP1 3768/4885TNF 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.